The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Sanofi's new chief executive, Belén Garijo, will see her tenure at the company kick-started by a strong 2026 first quarter, ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

Sanofi (SNY) beats Q1 estimates as Dupixent sales jump and EPS rises; guidance reaffirmed amid CEO transition and pipeline ...

Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions ...

Major global companies including Costco, Sanofi, and key regional banks have announced notable dividend increases in 2026, underscoring confidence in earnings and shareholder returns. The moves come ...

Sanofi India reported a 14% decline in Q1 net profit to ₹102.6 crore and a 4.9% drop in revenue to ₹472.3 crore. EBITDA fell ...

Sanofi Consumer Healthcare India Ltd reported a 35.6% rise in Q1 net profit to ₹67.8 crore, driven by a 32.8% jump in revenue ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...